|
|
||||||||
1 Departments of Cardiology and
Medicine, Royal Perth Hospital and The University of Western Australia,
Perth, Western Australia 6001;
2 Department of Biochemistry,
Royal Perth Hospital, Perth, Western Australia 6001;
3 Australian Institute of Sport, The deletion (D)
allele of the gene for angiotensin-converting enzyme (ACE) is
associated with higher plasma and tissue levels of the enzyme and has
also been related to a variety of cardiovascular complications,
particularly myocardial infarction. On the basis of indirect evidence,
we hypothesized that inheritance of the D allele would contribute to
elite athletic ability. Over a period of 4 yr, 120 Caucasian athletes
who were national (Australian) representatives in sports demanding a
high level of aerobic fitness were recruited. Their ACE genotypes were
compared with those of a community control group recruited randomly
from the electoral roll. There was no difference in ACE genotype
frequencies between the two groups. The DD genotype frequency was 30%
in athletes and 29% in the control group, and the II genotype
frequency was 22.5 and 22%, respectively. The results do not exclude
the possibility that ACE genotype could be related to some attribute
relating to a specific type of elite athletic ability or that there may be a difference between genders. Larger studies are desirable.
deletion allele; insertion allele; inheritance; physical
performance
WE HYPOTHESIZED THAT the deletion (D) allele of the
angiotensin-converting enzyme (ACE) gene might contribute to elite
athletic ability, on the basis of the following tentative evidence: ACE (which converts angiotensin I to angiotensin II) is widely distributed in cell types, including skeletal muscle (10) and, at least in heart
muscle, the enzyme level is higher in D homozygotes than in those with
ID or II genotypes (3, 11), where I is the insertion allele; and
angiotensin II is a growth factor for cardiac myocytes and fibroblasts
(12) and vascular smooth muscle cells (4). Furthermore, inheritance of
the D allele may relate not only to myocardial infarction (1, 13) but
also to processes such as ventricular hypertrophy (15) and restenosis
after coronary balloon angioplasty (17), the latter being regarded as a
repair process after vascular wall damage. There is also experimental evidence that angiotensin II is involved more generally in tissue repair (18), and overrepresentation of the DD genotype in centenarians (14) suggested to us (16) that augmented tissue repair responses could
be involved in this apparent paradox. Such an effect, coupled with
effects on cell growth, would be advantageous to the development of
elite athletic ability and sustained high-level performance. On the
other hand, there is recent evidence that the II genotype might result
in a beneficial training effect in army recruits (6).
The study group of 81 men and 39 women, aged 30 ± 14 (SD) yr,
recruited from 1994 to the present, was restricted to those who were,
or had been, national (Australian) representatives in highly aerobic
sports (hockey, 26; cycling, 25; skiing, 21; track and field, 15;
swimming, 13; rowing, 7; gymnastics, 5; other, 8). That is,
participants in sports in which a high level of physical performance
was not required, such as archery and pistol shooting, or those, such
as weight lifting, requiring primarily muscular strength, were not included.
Their results were compared with those of a community control group of
healthy subjects, aged 40 ± 6 yr, recruited from the electoral roll
(347 men, 338 women). ACE genotyping was carried out as previously
described (17).
Figure 1 illustrates the distribution of
genotypes in the athletes and control subjects and the close agreement
between the two groups, in which the genotypes were, respectively, DD,
30 and 29%; ID, 47.5 and 49%; and II, 22.5 and 22%. The odds ratio for athletes to have the DD genotype was 1.06 (95% confidence interval
0.69-1.62) and the II genotype 1.02 (95% confidence interval 0.64-1.62). Allele frequencies in the athlete and control groups were, respectively, D, 54 and 53%; and I, 46 and 47%, the odds ratio
for the D allele in athletes being 1.02 (95% confidence interval
0.77-1.34).
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
METHODS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES

View larger version (12K):
[in a new window]
Fig. 1.
Angiotensin-converting enzyme (ACE) genotype distribution in elite
athletes and control subjects, showing close concordance between 2 groups. D, deletion allele; I, insertion allele.
Five of the athletes included in the above analysis were gymnasts, and eight others competed in sports that possibly did not require an excellent level of aerobic fitness. Excluding those from the analysis did not alter the interpretation, the genotypes in the remaining 107 athletes being DD, 34 (32%), ID, 49 (46%), and II, 24 (22.4%); the odds ratio for athletes to have the DD genotype was 1.15 (95% confidence interval 0.74-1.79), and that for the II genotype was 1.01 (95% confidence interval 0.62-1.65). The numbers studied would have detected, with 90% power, a difference of 15% in the frequency of DD and 14% in that of II genotypes between the two groups; that is, for the DD genotype a frequency of 29 plus 15%, or 44%, would have been detected, and, for the II genotype, 36% would have been detected.
The numbers and proportion of female athletes were smaller than those for men and probably too small for valid comparison with the female control group or the athletic men. There were 75 male athletes among the 107 described above: DD, 30 (40%); ID, 29 (39%); II, 16 (21%); the odds ratio of DD for athleticism was 1.50 (95% confidence interval 0.89-2.50) and of II genotype was 0.98 (95% confidence interval 0.54-1.81). Although 8 of 32 female athletes had the II genotype, it is interesting and provocative that only 4 had the DD genotype.
| |
DISCUSSION |
|---|
|
|
|---|
Montgomery et al. (6) recently reported that the I, rather than the D, allele was significantly associated with the ability of mountaineers to ascend to 7,000 m without oxygen. This particular observation could be related to the specific attribute studied. As reviewed by Cargill and Lipworth (2), the renin-angiotensin system has an important influence on the pulmonary vasculature. It has been subsequently found that exposure to hypoxia increases the expression of ACE in the small pulmonary arteries of the rat and that the pulmonary hypertensive response to hypoxia is reduced by ACE inhibition (7, 8) and specific angiotensin II type 1 receptor inhibition (8, 19). It might be postulated that subjects with the DD genotype have more pulmonary ACE, a more active pulmonary renin-angiotensin system, and greater pulmonary vasoconstriction in response to hypoxia, whereas those with the II genotype are selected for the ability to withstand hypoxia. This hypothesis could be consistent with another recent observation (H. Montgomery, S. Myerson, R. Budget, H. Hemingway, and S. Humphries, personal communication) that the I allele frequency is directly related to the distance over which elite runners compete, suggesting a relationship with some aspect of endurance. However, this proposal is quite contrary to a recent preliminary finding that susceptibility to high-altitude pulmonary hypertension is greater in those with the II genotype (9). That result seems to contradict the finding in mountaineers (6) and was also surprising to the authors, who postulated linkage disequilibrium with some other gene; clearly, the whole question requires further examination, and in larger numbers of subjects.
The finding quoted above on the mountaineers (6) was complemented by a further finding that, after 10 wk of physical training of male army recruits, the ability to perform elbow flexion against resistance was significantly enhanced by inheritance of the I allele (6). However, the results of training of such a community group would not necessarily extrapolate to elite athletic performance, which is likely to depend on complex interactions among musculoskeletal adaptations, cardiovascular and pulmonary variables, tissue repair, and metabolic (5) and psychological factors. Montgomery et al. (5) have subsequently reported that, among the 81 male army recruits studied, those having the II genotype tended to gain total and nonfat mass during training, whereas D carriers tended to lose fat mass, the results being significantly different between these genotypes. This suggests metabolic dependence on ACE genotype, and the implications are unclear but would almost certainly differ among sports.
Our study would have detected an incidence of the II genotype of 40%, which was the incidence of that genotype in the very small group of high-altitude mountaineers (6). However, although we included over 100 athletes, we still did not have sufficient power to detect a smaller, and possibly important, ACE genotype influence on elite athleticism. However, there was no suggestion that the II genotype conferred elite athletic ability and, in men, there was a trend toward the DD genotype. The trend was the opposite in women, but the numbers were too small to draw conclusions. We also had to include athletes involved in a range of sports to obtain sufficient numbers at a truly elite level of physical performance. Our results must, therefore, be regarded as preliminary, but they, and other recent studies (5, 6; H. Montgomery, S. Myerson, R. Budget, H. Hemingway, and S. Humphries, personal communication), emphasize the importance of carrying out very large studies, together with observations on physiological mechanisms, on both male and female athletes involved in various types of sporting activities.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Dr. Carmel Goodman, Steve Lawrence, Dave Bishop, Martin Fitzsimmons, Matt Spencer, and Steve Morris for assistance with athlete recruitment; Dr. Konrad Jamrozik for documentation of normal control subjects; and Stacy Cartwright for technical assistance.
| |
FOOTNOTES |
|---|
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests and other correspondence: R. R. Taylor, Dept. of Cardiology, Royal Perth Hospital, Wellington St., Perth, Western Australia 6000, Australia (E-mail: heletoey{at}rph.health.wa.gov.au).
Received 23 October 1998; accepted in final form 17 May 1999.
| |
REFERENCES |
|---|
|
|
|---|
1.
Cambien, F.,
O. Poirier,
L. Lecerf,
A. Evans,
J.-P. Cambou,
D. Arveiler,
G. Luc,
J.-M. Bard,
L. Bara,
S. Ricard,
L. Tiret,
P. Amouyel,
F. Alhenc-Gelas,
and
F. Soubrier.
Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction.
Nature
359:
641-644,
1992[Medline].
2.
Cargill, R. I.,
and
B. J. Lipworth.
The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vasculature.
Br. J. Clin. Pharmacol.
40:
11-18,
1995[Medline].
3.
Danser, A. H. J.,
M. A. D. H. Schalekamp,
W. A. Bax,
A. M. van den Brink,
P. R. Saxena,
G. A. J. Riegger,
and
H. Schunkert.
Angiotensin-converting enzyme in the human heart. Effect of the deletion/insertion polymorphism.
Circulation
92:
1387-1388,
1995[Medline].
4.
Itoh, H.,
M. Mukoyama,
R. E. Pratt,
G. H. Gibbons,
and
V. J. Dzau.
Multiple autocrine growth factors modulate vascular smooth muscle cell growth response to angiotensin II.
J. Clin. Invest.
91:
2268-2274,
1993.
5.
Montgomery, H.,
P. Clarkson,
M. Barnard,
J. Bell,
A. Brynes,
C. Dollery,
J. Hajnal,
H. Hemingway,
D. Mercer,
P. Jarman,
R. Marshall,
K. Prasad,
M. Rayson,
N. Saeed,
P. Talmud,
L. Thomas,
M. Jubb,
M. World,
and
S. Humphries.
Angiotensin-converting-enzyme gene insertion/deletion polymorphism and response to physical training.
Lancet
353:
541-545,
1999[Medline].
6.
Montgomery, H. E.,
R. Marshall,
H. Hemingway,
S. Myerson,
P. Clarkson,
C. Dollery,
M. Hayward,
D. E. Holliman,
M. Jubb,
M. World,
E. L. Thomas,
A. E. Brynes,
N. Saeed,
N. Barnard,
J. D. Bell,
K. Prasad,
M. Rayson,
P. J. Talmud,
and
S. E. Humphries.
Human gene for physical performance.
Nature
393:
221-222,
1998[Medline].
7.
Morrell, N. W.,
E. N. Atochina,
K. G. Morris,
S. M. Danilov,
and
K. R. Stenmark.
Angiotensin converting enzyme expression is increased in small pulmonary arteries of rats with hypoxia-induced pulmonary hypertension.
J. Clin. Invest.
96:
1823-1833,
1995.
8.
Morrell, N. W.,
K. G. Morris,
and
K. R. Stenmark.
Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension.
Am. J. Physiol.
269 (Heart Circ. Physiol. 38):
H1186-H1194,
1995
9.
Morrell, N. W.,
A. S. Sarybaev,
A. Alikhan,
M. M. Mirrakhimov,
and
A. A. Aldashev.
ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders.
Lancet
353:
814,
1999[Medline].
10.
Reneland, R.,
and
H. Lithell.
Angiotensin-converting enzyme in human skeletal muscle. A simple in vitro assay of activity in needle biopsy specimens.
Scand. J. Clin. Lab. Invest.
54:
105-111,
1994[Medline].
11.
Rigat, B.,
C. Hubert,
F. Alhenc-Gelas,
F. Cambien,
P. Corvol,
and
F. Soubrier.
An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels.
J. Clin. Invest.
86:
1343-1346,
1990.
12.
Sadoshima, J.-I.,
and
S. Izumo.
Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts: critical role of the AT1 receptor subtype.
Circ. Res.
73:
413-423,
1993[Abstract].
13.
Samani, N. J.,
J. R. Thompson,
L. O'Toole,
K. Channer,
and
K. L. Woods.
A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction.
Circulation
94:
708-712,
1996[Medline].
14.
Schächter, F.,
L. Faure-Delanef,
F. Guenot,
H. Rouger,
P. Froguel,
L. Lesueur-Ginot,
and
D. Cohen.
Genetic associations with human longevity at the APOE and ACE loci.
Nat. Genet.
6:
29-32,
1994[Medline].
15.
Schunkert, H.,
H.-W. Hense,
S. R. Holmer,
M. Stender,
S. Perz,
U. Keil,
B. H. Lorell,
and
G. A. J. Riegger.
Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy.
N. Engl. J. Med.
330:
1634-1638,
1994
16.
Van Bockxmeer, F. M.
Apo E and ACE genes: impact on human longevity.
Nat. Genet.
6:
4-5,
1994[Medline].
17.
Van Bockxmeer, F. M.,
C. D. S. Mamotte,
F. A. Gibbons,
V. Burke,
and
R. R. Taylor.
Angiotensin-converting enzyme and apolipoprotein E genotypes and restenosis after coronary angioplasty.
Circulation
92:
2066-2071,
1995[Medline].
18.
Weber, K. T.
Metabolic responses of extracellular matrix in tissue repair.
Ann. Med.
29:
333-338,
1997[Medline].
19.
Zhao, L.,
R. al-Tubuly,
A. Sebkhi,
A. A. Owji,
D. J. Nunez,
and
M. R. Wilkins.
Angiotensin II receptor expression and inhibition in the chronically hypoxic rat lung.
Br. J. Pharmacol.
119:
1217-1222,
1996[Medline].
This article has been cited by other articles:
![]() |
C. Yamin, O. Amir, M. Sagiv, E. Attias, Y. Meckel, N. Eynon, M. Sagiv, and R. E. Amir ACE ID genotype affects blood creatine kinase response to eccentric exercise J Appl Physiol, December 1, 2007; 103(6): 2057 - 2061. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Amir, R. Amir, C. Yamin, E. Attias, N. Eynon, M. Sagiv, M. Sagiv, and Y. Meckel Human, Environmental & Exercise: The ACE deletion allele is associated with Israeli elite endurance athletes Exp Physiol, September 1, 2007; 92(5): 881 - 886. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R Thompson and S. A Binder-Macleod Association of Genetic Factors With Selected Measures of Physical Performance Physical Therapy, April 1, 2006; 86(4): 585 - 591. [Full Text] [PDF] |
||||
![]() |
B Walpole, T D Noakes, M Collins, and R J Trent Growth hormone 1 (GH1) gene and performance and post-race rectal temperature during the South African Ironman triathlon * Commentary Br. J. Sports Med., February 1, 2006; 40(2): 145 - 150. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. L. Grigorenko The Inherent Complexities of Gene-Environment Interactions J. Gerontol. B. Psychol. Sci. Soc. Sci., March 1, 2005; 60(suppl_Special_Issue_1): 53 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Heled, D. S. Moran, L. Mendel, A. Laor, E. Pras, and Y. Shapiro Human ACE I/D polymorphism is associated with individual differences in exercise heat tolerance J Appl Physiol, July 1, 2004; 97(1): 72 - 76. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. Williams, S. S. Dhamrait, P. T. E. Wootton, S. H. Day, E. Hawe, J. R. Payne, S. G. Myerson, M. World, R. Budgett, S. E. Humphries, et al. Bradykinin receptor gene variant and human physical performance J Appl Physiol, March 1, 2004; 96(3): 938 - 942. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Bahi, N. Koulmann, H. Sanchez, I. Momken, V. Veksler, A. X. Bigard, and R. Ventura-Clapier Does ACE inhibition enhance endurance performance and muscle energy metabolism in rats? J Appl Physiol, January 1, 2004; 96(1): 59 - 64. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Tiainen, S. Sipila, M. Alen, E. Heikkinen, J. Kaprio, M. Koskenvuo, A. Tolvanen, S. Pajala, and T. Rantanen Heritability of maximal isometric muscle strength in older female twins J Appl Physiol, January 1, 2004; 96(1): 173 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. M. Fuentes, M. Perola, A. Nissinen, and J. Tuomilehto ACE gene and physical activity, blood pressure, and hypertension: a population study in Finland J Appl Physiol, June 1, 2002; 92(6): 2508 - 2512. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Sonna, M. A. Sharp, J. J. Knapik, M. Cullivan, K. C. Angel, J. F. Patton, and C. M. Lilly Angiotensin-converting enzyme genotype and physical performance during US Army basic training J Appl Physiol, September 1, 2001; 91(3): 1355 - 1363. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Rankinen, B. Wolfarth, J.-A. Simoneau, D. Maier-Lenz, R. Rauramaa, M. A. Rivera, M. R. Boulay, Y. C. Chagnon, L. Perusse, J. Keul, et al. No association between the angiotensin-converting enzyme ID polymorphism and elite endurance athlete status J Appl Physiol, May 1, 2000; 88(5): 1571 - 1575. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |